Positive data from both DESTINY-Breast09 (TDXD-based) and PATINA (CDK4/6i maintenance) create a new dilemma. With similar PFS outcomes, the first-line choice for metastatic HER2+/HR+ patients now hinges on toxicity profiles and patient preference rather than a single efficacy winner.

The Right Choice trial shows CDK4/6 inhibitors are safer and better at delaying cancer progression than chemotherapy for patients with visceral metastases. However, this advantage doesn't translate to longer overall survival, suggesting the key benefit is improved quality of life and a less complex treatment regimen rather than longevity.

Experts assert that chemotherapy should not be used as first-line treatment for HR-positive metastatic breast cancer. Clinical trials show a CDK4/6 inhibitor with endocrine therapy provides better outcomes and tolerability than multi-agent chemotherapy, even for patients with aggressive, symptomatic visceral metastases, challenging the traditional use of chemo for rapid response.

A patient's time to progression on first-line CDK4/6 inhibitor therapy acts as an informal biomarker. A shorter duration, such as 14 months, is viewed by experts as "not so great" and indicates a degree of underlying endocrine resistance that influences subsequent treatment strategies.

The ELEGANT trial uses a "switch strategy," introducing elicestrin only after 2-5 years of standard therapy. This design pragmatically adapts to the evolving clinical landscape where CDK4/6 inhibitors are now standard initial treatment, ensuring the trial's relevance by testing the drug in a post-CDK4/6 inhibitor setting.

Three major trials (RIGHT Choice, PADMA, OMBRE) definitively show that starting with a CDK4/6 inhibitor plus endocrine therapy is superior to upfront chemotherapy for newly diagnosed, symptomatic metastatic breast cancer. This approach provides better progression-free survival without the toxicity of chemotherapy and, critically, does not result in a slower time to response.

When choosing an adjuvant CDK4/6 inhibitor for high-risk HR+ breast cancer, clinicians favor abemaciclib. The key deciding factors are its proven overall survival (OS) benefit from the MonarchE trial and a more appealing two-year treatment course, compared to ribociclib's three-year duration and not-yet-mature OS data.

New CDK inhibitors that also target CDK2 show great activity in models resistant to current CDK4/6 agents. Instead of being reserved for later use, they are already being tested in frontline trials. The strategy, similar to that of ALK inhibitors in lung cancer, is that using the best drug first may prevent or significantly delay the onset of resistance.

Data from multiple trials (EMERALD, VERITEC-2) reveal that the duration of a patient's response to a prior CDK4/6 inhibitor acts as a key predictive biomarker. Patients who benefited from CDK4/6 inhibitors for longer periods (e.g., >12-18 months) subsequently experienced a significantly greater progression-free survival benefit from oral SERD therapy.